Cullinan Therapeutics (CGEM) Total Liabilities (2020 - 2026)

Cullinan Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $36.8 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 32.22% year-over-year to $36.8 million in Q1 2026; TTM through Mar 2026 was $36.8 million, a 32.22% increase from a year earlier, with the FY2025 full-year figure at $39.6 million, up 25.87% from the prior year.
• Total Liabilities fell to $36.8 million in Q1 2026 per CGEM's latest filing, from $39.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $62.6 million in Q2 2022 and bottomed at $18.0 million in Q1 2022.
• The 5-year median for Total Liabilities is $28.2 million (2025), against an average of $30.4 million.
• Across the five-year window, Total Liabilities jumped 977.43% in 2022 and slumped 64.22% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $26.1 million in 2022, then advanced by 16.1% to $30.3 million in 2023, then grew by 3.99% to $31.5 million in 2024, then climbed by 25.87% to $39.6 million in 2025, then retreated by 7.14% to $36.8 million in 2026.
• Per Business Quant, the three latest CGEM Total Liabilities figures stand at $36.8 million (Q1 2026), $39.6 million (Q4 2025), and $32.8 million (Q3 2025).